Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Course Instructor

Abby Massey

Capstone Semester

Spring 2022

Date of Graduation



To determine if long-acting injectables cabotegravir and rilpivirine are non-inferior to oral antiretroviral therapy at maintaining viral load suppression below 50 copies per milliliter of serum. Design: Systematic literature review. Methods: A search was done in PubMed using the terms “HIV + cabotegravir” or “HIV + cabotegravir, rilpivirine drug combination.” Limitations included non-randomized control trials, comparison of injectable regimens directly or injectables to placebo, studies that evaluate compliance or side effects only, and studies with small sample sizes. Results: Meta-analysis revealed that continued use of injectables was sufficient in maintaining viral suppression at 93.6%, 92.5%, and 94% in each of the respective studies. This demonstrated non-inferiority to oral therapy. Conclusion: Overall, the three studies randomized participants in oral or long acting therapies after an oral induction period. Long-acting injectable formulations were proven to be non-inferior in the maintenance of viral load suppression. Use of monthly injectable antiretrovirals offers an alternative for increased compliance to many people living with HIV. Efficacy of long-acting injectables as initial therapy and their use in the pediatric population need further study.

Document Type




To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.